BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer - World R&D Summit in Boston

Bergen, Norway, July 26 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focussed on developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce that Murray Yule, MD, PhD, Clinical Development Officer at BerGenBio, will present an outline of the phase II clinical development programme of BerGenBio’s lead product, BGB324, in non-small cell lung cancer (NSCLC) at the Precision: Lung Cancer conference in Boston, July 25-26, 2017.

The presentation will take place on Wednesday 26, 3pm EST and will cover recent evidence of the benefits of selective AXL inhibition in order to overcome therapy resistance and immune escape as well as boost anti-tumour immunity. Dr Yule will discuss in detail the scientific and clinical rationale underpinning BerGenBio’s phase II clinical trial portfolio with BGB324 in NSCLC in combination with chemo-, targeted and immunotherapy. The aim of these clinical studies is to deliver proof-of-concept of BGB324’s potential to counteract AXL driven immune evasion and acquired resistance to therapy thereby uniquely synergising with and enhancing current and emerging therapies.

About NSCLC  

It is estimated that more than 220,000 new cases of lung cancer will be diagnosed in the US in 2017 and it is the leading cause of cancer death. 65% of NSCLCs are of adenocarcinoma pathology. Although various treatments exist for NSCLC, they are often curtailed by acquired resistance to therapy and immune evasion. Novel treatments overcoming these mechanisms in NSCLC are urgently required.  

About BerGenBio ASA 

BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the essential role of AXL kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive haematological and solid cancers.

BerGenBio’s lead product, BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in six Phase II clinical trials in major cancer indications with read-outs expected in the second half of 2018. It is the only selective AXL inhibitor in clinical development.

The clinical trials are:

• BGB324 as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS)
• BGB324 with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small cell lung cancer (NSCLC)
• BGB324 with KEYTRUDA® (pembrolizumab) in advanced NSCLC (adenocarcinoma of the lung), and
• BGB324 with KEYTRUDA® in triple negative breast cancer (TNBC).

The clinical trials combining BGB324 with KEYTRUDA® in NSCLC and TBNC are conducted in collaboration with Merck & Co. Inc. (MSD).

In addition, a number of investigator-led trials are underway, including a trial to investigate BGB324 with either MEKINIST® (trametinib) and TAFINLAR® (dabrafenib) or KEYTRUDA® in advanced melanoma as well as a trial exploring TAXOTERE® (docetaxel) in advanced non-small-cell lung cancer (NSCLC).

BerGenBio is simultaneously developing a companion diagnostic test that will be able to identify patient subpopulations most likely to benefit from the treatment. This will facilitate more efficient registration trials and support a precision medicine approach in reimbursement and commercialisation strategy. 

The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149, an anti-AXL monoclonal antibody.

For further information, please visit: www.bergenbio.com

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech.  

-Ends-

Contacts  

Richard Godfrey

 CEO, BerGenBio ASA

+47 917 86 304

Media Relations

David Dible, Mark Swallow, Marine Perrier

Citigate Dewe Rogerson

bergenbio@citigatedr.co.uk
 

+44 207 638 9571

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Tags: